Mylan/Natco, Sandoz/Momenta Stew As Teva Cements Copaxone Loyalty
This article was originally published in PharmAsia News
Executive Summary
Teva’s multiple sclerosis drug Copaxone lost patent protection about three weeks ago. But according to some analysts an immediate generic substitution is still up in the air and the company has not lost the opportunity to capitalize in the interim by switching patients to a new three-injections-a-week formulation.